VAFSEO Film-coated tablet Ref.[50970] Active ingredients: Vadadustat

Source: European Medicines Agency (EU)  Revision Year: 2023  Publisher: AKEBIA EUROPE Limited, 70 Sir John Rogersons Quay, Dublin 2, Co. Dublin, D02 R296, Ireland

Product name and form

Vafseo 150 mg film-coated tablets.

Vafseo 300 mg film-coated tablets.

Vafseo 450 mg film-coated tablets.

Pharmaceutical Form

Film-coated tablet.

Vafseo 150 mg film-coated tablets: Round, white tablets 8 mm in diameter, debossed with “VDT” on one side and “150” on the other side.

Vafseo 300 mg film-coated tablets: Oval, yellow tablets 8 mm in width, 13 mm in length, debossed with “VDT” on one side and “300” on the other side.

Vafseo 450 mg film-coated tablets: Oval, pink tablets 9 mm in width, 15 mm in length debossed with “VDT” on one side and “450” on the other side.

Qualitative and quantitative composition

Vafseo 150 mg film-coated tablets: Each 150 mg film-coated tablet contains 150 mg of vadadustat.

Vafseo 300 mg film-coated tablets: Each 300 mg film-coated tablet contains 300 mg of vadadustat.

Vafseo 450 mg film-coated tablets: Each 450 mg film-coated tablet contains 450 mg of vadadustat.

For the full list of excipients, see section 6.1.

Active Ingredient Description
Vadadustat

Vadadustat is a hypoxia-inducible factor prolyl-hydroxylase inhibitor which leads to increased cellular levels of hypoxia-inducible factor thereby stimulating endogenous erythropoietin (EPO) production, increasing iron mobilization and red blood cell production, resulting in gradual rate of rise in Hb.

List of Excipients

Tablet core:

Microcrystalline cellulose (E460)
Sodium starch glycolate
Hypromellose (E464)
Silica, colloidal anhydrous (E551)
Magnesium stearate

Tablet coating:

Polyvinyl alcohol (E1203)
Macrogol (E1521)
Talc (E553b)
Titanium dioxide (E171)
Yellow iron oxide (E172) (Vafseo 300 mg film-coated tablets)
Iron oxide red (E172) (Vafseo 450 mg film-coated tablets)
Ferrosoferric oxide (E172) (Vafseo 450 mg film-coated tablets)

Pack sizes and marketing

Vafseo 150 mg film-coated tablets:

28 tablets in 2 PVC/aluminium foil blisters with 14 × 150 mg film-coated tablets
98 tablets in 7 PVC/aluminium foil blisters with 14 × 150 mg film-coated tablets

Vafseo 300 mg film-coated tablets:

28 tablets in 2 PVC/aluminium foil blisters with 14 × 300 mg film-coated tablets
98 tablets in 7 PVC/aluminium foil blisters with 14 × 300 mg film-coated tablets

Vafseo 450 mg film-coated tablets:

28 tablets in 2 PVC/aluminium foil blisters with 14 × 450 mg film-coated tablets
98 tablets in 7 PVC/aluminium foil blisters with 14 × 450 mg film-coated tablets

Not all pack sizes may be marketed.

Marketing authorization holder

AKEBIA EUROPE Limited, 70 Sir John Rogerson’s Quay, Dublin 2, Co. Dublin, D02 R296, Ireland

Marketing authorization dates and numbers

EU/1/23/1725/001
EU/1/23/1725/002
EU/1/23/1725/003
EU/1/23/1725/004
EU/1/23/1725/005
EU/1/23/1725/006

Drugs

Drug Countries
VAFSEO Austria, Estonia, Croatia, Ireland, Italy, Japan, Lithuania

© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.